Connect Biopharma's partner submits new drug application in China

Connect Biopharma Holdings (NASDAQ:CNTB) announced its collaborator Simcere Pharmaceutical submitted a New Drug Application for rademikibart to China's NMPA for adult and adolescent atopic dermatitis, targeting a significant 70 million-patient market. This regulatory progress positions CNTB to receive up to $110 million in milestone payments and tiered low double-digit royalties on Greater China sales. Concurrently, Connect Biopharma recently reported positive Phase 2b clinical data for rademikibart in eosinophilic-driven type 2 asthma, demonstrating significant improvements, and has initiated a Phase 2 study with topline data anticipated in the first half of 2026, underscoring the drug's multi-indication potential and future catalysts.

Analysis

Connect Biopharma (CNTB) has achieved a significant regulatory milestone with its partner, Simcere Pharmaceutical, submitting a New Drug Application to China's NMPA for rademikibart in atopic dermatitis. This event advances the drug toward a substantial market opportunity, estimated at 70 million patients in China, and unlocks the potential for CNTB to receive up to $110 million in milestone payments plus low double-digit royalties, a considerable sum relative to its $63 million market capitalization. Beyond this near-term catalyst, the drug's platform potential is reinforced by recent positive Phase 2b data in eosinophilic-driven asthma, which demonstrated up to a 74% reduction in exacerbation rates. The pipeline's forward momentum is further evidenced by the initiation of a Phase 2 study in acute asthma, with a key data readout anticipated in the first half of 2026. Despite these positive developments, it is critical to note that rademikibart remains an unapproved investigational drug, and its ultimate value is contingent on pending regulatory decisions in China and globally.

Key Decisions for Investors

• Given the China NDA submission and potential for milestone payments that exceed its current market cap, investors with high risk tolerance could view CNTB as a speculative investment with significant upside potential.
• Investors should closely monitor the NMPA's review process in China, as a potential approval would serve as the next major valuation catalyst and validate the commercial pathway for rademikibart.
• Long-term value is dependent on pipeline expansion, so it is prudent to track progress in the global asthma and COPD studies, with the H1 2026 topline data for the Phase 2 Seabreeze STAT study being a key future inflection point.
• Considering the stock's recent high volatility and the binary risks inherent in a pre-revenue biotech, any position should be sized to account for potential clinical or regulatory setbacks.